ULTRAGENYX PHARMACEUTICAL ($RARE) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of -$1.57 per share, beating estimates of -$1.65 by $0.08. The company also reported revenue of $139,290,000, missing estimates of $146,702,265 by $-7,412,265.
You can see Quiver Quantitative's $RARE stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ULTRAGENYX PHARMACEUTICAL Insider Trading Activity
ULTRAGENYX PHARMACEUTICAL insiders have traded $RARE stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $RARE stock by insiders over the last 6 months:
- EMIL D KAKKIS (President & CEO) has made 0 purchases and 4 sales selling 118,434 shares for an estimated $5,062,452.
- KARAH HERDMAN PARSCHAUER (EVP and Chief Legal Officer) has made 0 purchases and 3 sales selling 15,836 shares for an estimated $669,040.
- ERIK HARRIS (EVP & Chief Commercial Officer) sold 15,103 shares for an estimated $635,836
- JOHN RICHARD PINION (See Remarks) sold 14,439 shares for an estimated $607,881
- ERIC CROMBEZ (EVP and Chief Medical Officer) has made 0 purchases and 3 sales selling 9,707 shares for an estimated $405,485.
- THOMAS RICHARD KASSBERG (CBO & EVP) sold 6,028 shares for an estimated $253,778
- HOWARD HORN (Chief Financial Officer) sold 1,785 shares for an estimated $72,114
- THEODORE ALAN HUIZENGA (SVP, Chief Accounting Officer) sold 967 shares for an estimated $40,710
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ULTRAGENYX PHARMACEUTICAL Hedge Fund Activity
We have seen 147 institutional investors add shares of ULTRAGENYX PHARMACEUTICAL stock to their portfolio, and 158 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP removed 1,707,881 shares (-41.0%) from their portfolio in Q4 2024, for an estimated $71,850,553
- ALKEON CAPITAL MANAGEMENT LLC removed 1,325,000 shares (-44.0%) from their portfolio in Q4 2024, for an estimated $55,742,750
- SANDS CAPITAL MANAGEMENT, LLC removed 820,252 shares (-16.0%) from their portfolio in Q4 2024, for an estimated $34,508,001
- AQR CAPITAL MANAGEMENT LLC removed 763,826 shares (-73.1%) from their portfolio in Q4 2024, for an estimated $32,134,159
- VESTAL POINT CAPITAL, LP added 750,000 shares (+100.0%) to their portfolio in Q4 2024, for an estimated $31,552,500
- DEEP TRACK CAPITAL, LP added 653,513 shares (+inf%) to their portfolio in Q4 2024, for an estimated $27,493,291
- PRICE T ROWE ASSOCIATES INC /MD/ removed 556,231 shares (-18.1%) from their portfolio in Q4 2024, for an estimated $23,400,638
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ULTRAGENYX PHARMACEUTICAL Price Targets
Multiple analysts have issued price targets for $RARE recently. We have seen 2 analysts offer price targets for $RARE in the last 6 months, with a median target of $89.5.
Here are some recent targets:
- An analyst from Piper Sandler set a target price of $115.0 on 03/17/2025
- An analyst from Morgan Stanley set a target price of $64.0 on 03/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
